Back to search results

TRITON-CM: A Study of Nucresiran for Transthyretin Amyloidosis With Cardiomyopathy

This study, called TRITON-CM, is evaluating a drug called nucresiran for people with transthyretin amyloidosis with cardiomyopathy (a heart condition where abnormal proteins build up in the heart). You may be able to join if you are between 18 and 85 years old, have a diagnosis of this condition, and have a history of heart failure. The study aims to see if nucresiran can reduce deaths and heart-related problems compared to a placebo (Sterile Normal Saline, which is salt water). It will also look at how nucresiran affects your health and quality of life. The study plans to enroll 1750 people, but its current recruitment status is unclear.

Study design
This interventional study plans to enroll 1750 participants. It compares nucresiran to a placebo (Sterile Normal Saline).
What's involved
You would receive either nucresiran or Sterile Normal Saline as an injection under the skin every six months.
Compensation
Not stated in the trial record.
Follow-up
The study will track outcomes like death and heart events from the start of the study until the end of the double-blind period, which is estimated to be 32 months, up to a maximum of 5 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07052903

TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Recruiting
PHASE3Ages 18–85InterventionalTreatment
Alnylam Pharmaceuticals
~1,750 participants
Updated 2026-08-14 on ClinicalTrials.gov
What's tested:NucresiranSterile Normal Saline (0.9% NaCl)

At a glance

Recruiting sites
250 of 251 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Composite outcome of all-cause mortality and recurrent cardiovascular [CV] events (CV hospitalizations and urgent heart failure [HF] visits)
Measured over Baseline to end of double-blind period (estimated 32 months, maximum 5 years)

Conditions

Transthyretin Amyloidosis With Cardiomyopathy

Explore related trials

ATTR Amyloidosis

Where it's being run

251 sites across 57 states
Japan18
Spain18
France16
Italy15
China12
Belgium11
Brazil11
Germany11

Study leadership

  • Medical Director · STUDY_DIRECTOR · Alnylam Pharmaceuticals

Who to contact

Clinical Trial Information Line
[email protected]
1-877-ALNYLAM
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Has documented diagnosis of ATTR amyloidosis with cardiomyopathy including those with hereditary ATTR (hATTR) or wild-type ATTR (wATTR) amyloidosis.
Has medical history of heart failure (HF) with at least 1 prior hospitalization for HF or signs and symptoms that require treatment with a diuretic.
Has screening N-terminal prohormone B-type natriuretic peptide (NT-proBNP) \>300 ng/L and \<8500 ng/L; In patients with permanent or persistent atrial fibrillation, screening NT-proBNP \>600 ng/L and \<8500 ng/L.
Patients may be receiving approved TTR stabilizers for ATTR amyloidosis (eg, tafamidis, acoramidis) and may be receiving background therapy for HF at the discretion of the Investigator.

Exclusion

Has New York Heart Association (NYHA) Class IV HF; or NYHA Class III heart failure AND ATTR Amyloidosis Disease Stage 3.
Has a polyneuropathy disability (PND) Score IIIa, IIIb, or IV.
Has an estimated glomerular filtration rate (eGFR) of \<30 mL/min/1.73m\^2 at screening.
Has received prior or currently receiving TTR-lowering therapy

What this trial measures

  • Composite outcome of all-cause mortality and recurrent cardiovascular [CV] events (CV hospitalizations and urgent heart failure [HF] visits)Baseline to end of double-blind period (estimated 32 months, maximum 5 years)

    All-cause mortality and recurrent CV events (CV hospitalizations and urgent HF visits) will be compared between treatment groups using an Andersen-Gill model.